• Mashup Score: 0
    Innovations in Evaporative DED and Novel Cataract Surgery Technologies - 1 year(s) ago

    An expert panel, moderated by Eric D. Donnenfeld, MD, FAAO, and featuring Mark Lobanoff, MD; Marguerite McDonald, MD, FACS; and Karl G. Stonecipher, MD, will discuss innovations from B+L: MIEBO ™ (perfluorohexyloctane ophthalmic solution) – what it is, how it works, and review of pivotal efficacy and safety data for Rx treatment of the signs and symptoms of dry eye disease IC-8 ® Apthera ™ IOL – a small aperture technology IOL designed to help patients achieve a clear, continuous range of vision from near

    Source: avenue.live
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of CRSToday
      CRSToday

      #ad | Join @BauschLomb in San Francisco to celebrate the launch of MIEBO™ (perfluorohexyloctane ophthalmic solution)! Listen as an expert panel highlights innovations in evaporative DED and novel surgical technologies. Register here: https://t.co/a9IuXyhuLW https://t.co/yKrMg5vZ2W

  • Mashup Score: 0
    Securing Premium Patient Happiness - 1 year(s) ago

    By Christine Yue Leonard, Senior Associate Editor P ati ent unhappiness inevitably comes with the premium lens territory at one point or another, but there are a number of steps surgeons can take both preoperatively and postoperatively to reduce the likelihood of these trying scenarios. “You have to have a mechanism for dealing with the unhappy patient once they’ re on the other side of surgery,” says Kevin Miller, MD, a professor of clinical ophthalmology and the Kolokotrones Chair in Ophthalmology at

    Source: www.reviewofophthalmology.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of RevOphth
      RevOphth

      Securing Premium Patient Happiness🔐 How to do more than just “hope for the best” when it comes to premium IOL satisfaction. "The worst thing you can do is abandon the patient.” https://t.co/ScPt4nMcVZ #cataractsurgery #cataract #cataractsurgeon #ophthalmology #refractivesurgery https://t.co/3apcGKQOJw

  • Mashup Score: 0
    Glaucoma Physician - Two-Year Omni Data Show Sustained Reductions in IOP, Medication Use - 1 year(s) ago

    ■ Encompassing the longest follow-up on the Omni Surgical System to date, 2-year results of the multicenter ROMEO study were published in Clinical Ophthalmology. With the technology employed both as a standalone procedure and in combination with cataract surgery, patients had continued significant reductions in IOP and medication usage at 24 months. There were no serious or unanticipated adverse events. “This longer-term data set representing patients treated at multiple centers throughout the country

    Source: www.glaucomaphysician.net
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of GlaucomaPhys
      GlaucomaPhys

      Results of the multicenter ROMEO study of the Omni Surgical System as a standalone procedure and in combination with cataract surgery showed that patients had continued significant reductions in IOP and medication usage at 24 months. https://t.co/I0u18ymPmt #glaucoma https://t.co/s0KkSwquPc

  • Mashup Score: 0
    Ophthalmology Management - OPHTHALMOLOGY MANAGEMENT 40 UNDER 40 - 1 year(s) ago

    E arlier this year, we asked you, our readers, for nominations for our inaugural 40 Under 40 list. The goal was to highlight the next generation of ophthalmology: 40 ophthalmologists under 40 years old who have achieved excellence in their field. You responded with more than 100 nominations, detailing the efforts by many young surgeons in research, innovation, leadership, teaching, entrepreneurship, academics, global health and more. Our selection committee voted on the nominees and whittled down the

    Source: www.ophthalmologymanagement.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of Ophthalmologymg
      Ophthalmologymg

      This week, we highlight @yasha_modi, director of Tele-Retina at @nyulangone where he is also an associate professor of ophthalmology specializing in retinal disease, uveitis and vitreoretinal surgery. https://t.co/JPKiT5FDpv #uveitis #vitreoretinalsurgery #retina #ophthalmology https://t.co/ovNLRUfxZm

  • Mashup Score: 0
    Retinal Physician - CLINICAL TRIAL UPDATE - 1 year(s) ago

    Purpose: This is a phase 1/2 study to assess the safety and efficacy of OCU410 for geographic atrophy secondary to dry age-related macular degeneration (AMD). Design: Randomized, sequential assignment, single masking Inclusion Criteria: Subjects 50 years of age or older. BCVA of approximately 24 letters or more using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (20/320 Snellen equivalent). Fundus autofluorescence (FAF) imaging shows: total GA area ≥ 2.5 and ≤ 17.5 mm2 (1 and 7 disk areas

    Source: www.retinalphysician.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of RetinalPhys
      RetinalPhys

      See what #retina #clinicaltrials have been launched and completed since our last issue: https://t.co/G2XArYhBIi #ophthalmology https://t.co/beH2vhskc7

  • Mashup Score: 0
    Overview - 1 year(s) ago

    Provider Statement This continuing education activity is provided by Support Statement This activity is supported by an educational grant from Genentech, a member of the Roche Group. Activity Description Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly enhanced visual and anatomical outcomes for patients with diabetic macular edema (DME) and…

    Source: cme.healio.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of Healio_OSN
      Healio_OSN

      Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly enhanced visual and anatomical outcomes for patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Earn credits today! https://t.co/wcTlW9QLdF https://t.co/OTwdutF7sC

  • Mashup Score: 0
    Five events make for a busy summer in retina - 1 year(s) ago

    Retina Specialist focuses on the latest advances in the diagnosis, medical management and surgical treatment of diseases of the retina, along with practical, real-world advice from leading clinicians and other experts on managing the successful retina practice.

    Source: www.retina-specialist.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of RetSpecMag
      RetSpecMag

      It was a busy summer in retina! ⬇️ 1. Aflibercept 8mg gets approved 2. FDA approves avacincaptad pegol for GA 3. What’s next for ONS-5010? 4. Pegcetacoplan injection kits pulled after vasculitis reports 5. PDS implantations may resume by year-end https://t.co/yypMO2Sj54 https://t.co/WuxjK8ajDy

Load More